# KB408 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kb408

> KB408, sponsored by Krystal Biotech, Inc. (KRYS): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KB408 |
| Codes | KB408 |
| Sponsor | Krystal Biotech, Inc. (KRYS) https://sec-api.dev/companies/krys/catalysts |
| Indications | with aatd |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: with AATD.
- First seen 2025-02-19, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001711279-26-000071): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm
- SEC Form 10-Q (accession 0001711279-26-000057): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm
- SEC Form 10-Q (accession 0001711279-26-000043): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000043/krys-20260331.htm
- SEC Form 10-K (accession 0001711279-26-000016): "In February 2024, we announced that we had dosed the first patient in our Phase 1 SERPENTINE-1 study evaluating KB408, delivered via a nebulizer, for the treatment of patients with AATD." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm
- SEC Form 10-Q (accession 0001711279-25-000087): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm
- SEC Form 10-Q (accession 0001711279-25-000077): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, single dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000077/krys-20250630.htm
- SEC Form 10-Q (accession 0001711279-25-000044): "In February 2024, we announced that we dosed the first patient in SERPENTINE-1, a Phase 1, open-label, single dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000044/krys-20250331.htm
- SEC Form 10-K (accession 0001711279-25-000008): "In February 2024, we announced that we had dosed the first patient in our Phase 1 SERPENTINE-1 study evaluating KB408, delivered via a nebulizer, for the treatment of patients with AATD." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000008/krys-20241231.htm
- SEC Form 10-K (accession 0001711279-25-000008): "In February 2024, we announced that we had dosed the first patient in SERPENTINE-1, a Phase 1, open-label, single dose escalation study evaluating KB408, delivered via a nebulizer, in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000008/krys-20241231.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-02-19, last confirmed 2025-02-19.
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000009): "Based on this promising initial data, the Company has simultaneously expanded Cohort 2 and opened Cohort 3 of SERPENTINE-1 for more comprehensive molecular assessments at both dose levels and expects to report results from both cohorts in 2H 2025." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/a4q24exhibit991pr.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-11-03, last confirmed 2026-02-17.
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000088): "•The Company continues to enroll in repeat dose Cohort 2B of SERPENTINE-1, the Company's open label dose escalation study evaluating KB408 in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype, and expects to report interim data for this cohort in 1H 2026." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-26-000018): "•The Company continues to enroll patients in the repeat dose Cohort 2B of SERPENTINE-1, the Company's open label dose escalation study evaluating KB408 in adult patients with AATD with a Pi*ZZ or a Pi*ZNull genotype, and expects to report interim data for this cohort in 2026." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/a4q25exhibit991pr.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kb408.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KB408 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kb408

```bibtex
@misc{secapidev_pdufa_kb408_20261116,
  title        = {KB408 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kb408}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kb408_20261116","title":"KB408 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kb408","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
